Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
Published on: November 8, 2024
Tofacitinib for the Treatment of Pyoderma Gangrenosum
Bharati Kochar1, Neel Herfarth2, Céline Mamie2
1Multidisciplinary Center for Inflammatory Bowel Disease, University of North Carolina, Chapel Hill, North Carolina; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
Abstract:
Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Angle Closure Glaucoma: Treatment

